Clinical Trial Update: Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451 [Phase 1]

View source ↗

Summary

Phase 1 single ascending dose study of AZD4451 in bipolar disorder completed to assess safety, tolerability, and pharmacokinetics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• AZD4451

Snippet

Sponsor: AstraZeneca | Conditions: Bipolar Disorder | Phase 1 | Status: COMPLETED